Dr. Victoria Garcia

Dr. Victoria E. Garcia DO, FACOOG


07/2002 – 06/2006       Cook County Hospital Obstetrics and Gynecology Internship and Residency Program Chicago, IL

08/1997 – 05/2002      DO, Nova Southeastern University College of Osteopathic Medicine Ft. Lauderdale, FL

08/1994 – 05/1997    MS, Barry University, Major: Biomedical Sciences Miami, FL

08/1989 – 05/1994     BS, Florida International University, Major: Biological Sciences Miami, FL



  • Board Certified in Obstetrics and Gynecology, since 10/2011
  • Permanent Florida License # OS 10504 2008 to Present
  • Florida Board of Health Level 3 Office Surgery License
  • Permanent Illinois License # 036115407
  • DEA # BG978xxxx
  • Basic Cardiac Life Support (BCLS)
  • Advanced Cardiac Life Support (ACLS)
  • Neonatal Resuscitation Provider (NRP)


2016 – Present            Doral Medical Research, LLC

2015 –  2016                   Universal Clinical Research Associates

2009 to Present          Dr. Victoria Garcia & Associates, LLC


Chancellor’s Medicine Scholarship

Full Medicine Scholarship Nova Southeastern University


12/2015                       Associate Clinical Professor FIU OB/GYN Residents

01/2015                        Associate Clinical Professor Medical Student NSU-COM OB/GYN


Fellow, American College of Osteopathic Obstetrics and Gynecology

Junior Fellow, American College of Obstetrics and Gynecology

Member, American Osteopathic Association

Member, American Medical Association

Member, Illinois Osteopathic Medical Society

Member, American Urogynecology Society

Member, Florida Medical Association

Member, Florida Obstetrics and Gynecology Society

Member, Florida Osteopathic Medical Association


Kendall Regional Medical Center

Palmetto General Hospital


NIH Certification

GCP Certification (CITI Program)


Principal Investigator

Merck Sharp & Dohme Corp: A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain. 2018

Janssen Pharmaceuticals: A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a/2b Study to Evaluate Safety, Reactogenicity, Regimen Selection, Immunogenicity and Efficacy of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women with Persistent HPV16 or 18 Infection of the Cervix. 2018

Bayer Pharmaceuticals: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of XXXXXX in subjects with uterine fibroids. 2018

Bayer Pharmaceuticals: A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of XXXXX in subjects with uterine fibroids. 2018

Myovant Sciences:  An international Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate XXXXX Co-Administered with ad without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids. 2017

Bayer Pharmaceuticals:  An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of XXXXX in subjects with uterine fibroids versus standard of care. 2017 NCT03194646

AbbVie: Phase III Fibroid Study; Menstrual flow research to XXX medication versus Placebo. 01/2016

AbbVie: Phase III Endometriosis Study to test the safe ty and efficacy of XXXX administered orally. 05/2013-05/2015(

Phase III Anemia Association with Uterine Fibroids 06/2012 to 01/2013

Phase III Evaluation of Safety, Pharmacokinetics, and Efficacy of XXXX Administered Vaginally on Woman with Uterine Fibroids. 01/2012 to 01/2013


A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase III Study to Evaluate Cardiovascular Outcomes of XXX, SO mg in addition to Standard of care in Subjects with type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular events

Phase III, Randomized, Double-Blind, Active-Controlled, Parallel -Group Study of the comparative Efficacy and Safety of XXX in subjects with Acute Otitis Externa

Phase IV Global Registry on Long-term Oral Anti-Thrombotic treatment in patients with Atrial Fibrillation Phase II and Ill

A Study in Japan and Ex-Japan to Characterized the Pharmacokinetic and Pharmacodynamic Response to Oteronel (XXX-700) in Chemotherapy Naïve patients with Castration -Resistant Prostate Cancer

An Open Label, Randomized, Comparison of the Immunogenicity and Safety of Human Insulin Basal Bolus Regimen (XXXX 70 -30) with the Sponsor Yeast based Human Insulin Basal Bolus Regimens, marketed in the United States (XXXX 70/30) in Type I Diabetes


An open Label study to evaluate the safety. Tolerability and Pharmacokinetics of XXXX in Combination with other anti-retroviral (ARVs) in antiretroviral treatment-experienced HIV-1 infected subjects,2012 – Cardiovascular Outcomes Study to evaluate the potential of XXXX to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2DM)


An Open Label, 52-week study to assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain Senior Research Project: Mode of Delivery in HIV infected Patients at Cook County Hospital


X Biotech USA, Inc: A Phase II, Open Label, Dose Escalation Study of  XXXXX in Patients with Moderate to Severe Hidradenitis Suppurativa


X Biotech USA Inc: A Phase II, Open Label, Dose Escalation Study of XXXXX in Patients with Moderate to Severe Atopic Dermatitis

Yiling Pharmaceutical, Inc: A Multi-Center, Randomized, Double-Blind, And Placebo-Controlled Phase II Clinical Study to Investigate the Safety and Efficacy Of Two Doses Of KT07 Compared To Placebo In Subjects with Acute Uncomplicated Influenza.



Master’s Thesis:                    The Role of Protein Kinas C Levels in Spontaneously Hypersensitive Rat

PI credentials:                       Elaris UF1 and UF2. “Elagolix therapy for Heavy Menstrual bleeding in Women with Uterine Fibroids” New England Journal of Medicine.



05/2009- Present                     Manoguayo Dominican Republic

01/2007-01/2009                      Family Health Partnership Clinic – Volunteer Clinic Gynecology Services/ Surgeries to indigent patients in the community.

03/2002                                   Medical Mission to Delhi, India

06/2001                                   Medical Mission to the Dominican Republic

01/2000                                   DOCARE Medical Mission to Antigua, Guatemala


REFRENCES:                         Upon request